ABSTRACT
Background@#and PurposeImpulse-control disorder is an important nonmotor symptom of Parkinson's disease (PD) that can lead to financial and social problems, and be related to a poor quality of life. A nationwide multicenter prospective study was performed with the aim of validating the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (K-QUIP-RS). @*Methods@#The K-QUIP-RS was constructed using forward and backward translation, and pretesting of the prefinal version. PD patients on stable medical condition were recruited from 27 movement-disorder clinics. Participants were assessed using the K-QUIP-RS and evaluated for parkinsonian motor and nonmotor statuses and for PD-related quality of life using a predefined evaluation battery. The test–retest reliability of the K-QUIP-RS was assessed over an interval of 10–14 days, and correlations between the KQUIP-RS and other clinical scales were analyzed. @*Results@#This study enrolled 136 patients. The internal consistency of the K-QUIP-RS was indicated by a Cronbach's α coefficient of 0.846, as was the test–retest reliability by a Guttman split-half coefficient of 0.808. The total K-QUIP-RS score was positively correlated with the scores for depression and motivation items on the Unified PD Rating Scale (UPDRS), Montgomery-Asberg Depression Scale, and Rapid-Eye-Movement Sleep-Behavior-Disorders Questionnaire. The total K-QUIP-RS score was also correlated with the scores on part II of the UPDRS and the PD Quality of Life-39 questionnaire, and the dopaminergic medication dose. @*Conclusions@#The K-QUIP-RS appears to be a reliable assessment tool for impulse-control and related behavioral disturbances in the Korean PD population.
ABSTRACT
PURPOSE: To evaluate the long-term (12 to 30 months) effect of L-dopa with part-time occlusion in patients in which occlusion therapy failed. METHODS: Seventeen eyes of 12 amblyopic children who failed with part-time occlusion (4 to 8 hours/day) treatment for a minimum period of 6 months were studied. The follow-up period was 12 to 30 months. The average best corrected visual acuity (BCVA) before treatment was 0.28+/-0.20 (0.05-0.5). After full informed consent was obtained from their parents, the children received levodopa (2 to 4 mg/kg) for 8 weeks combined with part-time occlusion and spectacles. RESULTS: The average age of the subjects was 7.0+/-2.7 years and the mean follow-up period was 23.7+/-7.7 (12 to 30) months. After the administration of levodopa for 8 weeks, 9 eyes (53%) showed improvement in BCVA, and only 4 eyes showing a mean regression of 0.20+/-0.11 logMAR visual acuities. The BCVA reached the maximum value after a mean of 8.47 months. After 8 weeks from baseline, 13 eyes (76%) reached the maximum BCVA. After 12 to 30 months of follow-up, 12 out of 17 eyes (70.6%) showed a BCVA improvement of 0.14+/-0.19 logMAR. CONCLUSIONS: After the long-term (12 to 30 months) follow-up, L-dopa with part-time occlusion in patients in which occlusion therapy failed showed improved visual acuities in 76% of the cases.